Wang, Yao <br/><br/>
Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.  [electronic resource] 

 -  Clinical immunology (Orlando, Fla.)  Dec 2014 
 - 160-75 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1521-7035 
<br/><br/><label>Standard No.: </label>10.1016/j.clim.2014.10.002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antigens, CD20--genetics<br/>Cell Line<br/>Combined Modality Therapy<br/>Cytotoxicity, Immunologic<br/>Female<br/>Gene Dosage<br/>Gene Order<br/>Humans<br/>Immunotherapy, Adoptive--adverse effects<br/>Lymphocyte Count<br/>Lymphoma, Large B-Cell, Diffuse--diagnosis<br/>Magnetic Resonance Imaging<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Positron-Emission Tomography<br/>Protein Binding<br/>Receptors, Antigen, T-Cell--genetics<br/>Recombinant Fusion Proteins--genetics<br/>T-Cell Antigen Receptor Specificity--immunology<br/>T-Lymphocytes--immunology<br/>Tomography, X-Ray Computed<br/>Treatment Outcome<br/>Tumor Necrosis Factor Receptor Superfamily, Member 9--genetics